References
- Couvreur P, Dubernet C, Puisieux F. Controlled drug delivery with nanoparticles: Current possibilities and future trends. Eur J Pharm Biopharm 1995; 41: 2–13
- Elkheshen SA, Ahmed SM, Al-Quadeib BT. Inclusion complexes of piroxicam with β-cyclodextrin derivatives in comparison with the natural β-cyclodextrin: in vitro and in vivo drug availability. Pharm Ind 2002; 64: 708–715
- Filipović-Grĉić J, Bećirević-Laćan M, Ŝkalko N, Jalšenjak I. Chitosan microspheres of nifepidine and nifepidine-cyclodextrin inclusion complex. Int J Pharm 1996; 135: 183–190
- Filipović-Grĉić J, Voinovich D, Moneghini M, Bećirević-Laćan M, Magarotto L, Jalšenjak I. Chitosan microspheres with hydrocortisone and hydrocortisone–hydroxypropyl-β-cyclodextrin inclusion complex. Eur J Pharm Sci 2000; 9: 373–379
- Gomez-Gaete C, Tsapis N, Besnard M, Bochot A, Fattal E. Encapsulation of dexamethasone into biodegradable polymeric nanoparticles. Int J Pharm 2007; 331: 153–159
- Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 2002; 6: 319–327
- Hausberger AG, DeLuca PP. Characterization of biodegradable poly(lactide-co-glycolide) polymers and microspheres. J Pharm Biomed Anal 1995; 13: 747–760
- Imai T, Irie T, Otagiri M, Uekama K, Yamasaki M. Comparative study on complexations of antiinflammatory drug flurbiprofen with β-cyclodextrin and methylated β-cyclodextrins. J Inclusion Phenom Macrocyc Chem 1984; 2: 597–604
- Lamprecht A, Ubrich N, Yamamoto H, Schafer U, Takeuchi H, Maincent P, Kawashima Y, Lehr CM. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther 2001; 299: 775–781
- Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J Pharmacol Exp Ther 2005; 315: 196–202
- Loftsson T, Duchêne D. Cyclodextrins and their therapeutic applications. Int J Pharm 2007; 329: 1–11
- Maestrelli F, Cecchi M, Cirri M, Capasso G, Mennini N, Mura P. Comparative study of oxaprozin complexation with natural and chemically modified cyclodextrins in solution and in the solid state. J Inclusion Phenom Macrocyc Chem 2009; 63: 17–25
- Maestrelli F, García-Fuentes M, Mura P, Alonso MJ. A new drug nanocarrier consisting of chitosan and hydroxypropylcyclodextrin. Eur J Pharm Biopharm 2006; 63: 79–86
- Maestrelli F, Zerrouk N, Cirri M, Mennini N, Mura P. Microspheres for colonic delivery of ketoprofen-hydroxypropyl-ß-cyclodextrin complex. Eur J Pharm Sci 2008; 34: 1–11
- Mainardes RM, Evangelista RC. PLGA nanoparticles containing praziquantel: Effect of formulation variables on size distribution. Int J Pharm 2005; 290: 137–144
- Meissner Y, Pellequer Y, Lamprecht A. Nanoparticles in inflammatory bowel disease: Particle targeting versus pH-sensitive delivery. Int J Pharm 2006; 316: 138–143
- Otero Espinar FJ, Anguiano Igea S, Blanco Mendez J, Vila Jato JL. Reduction in the ulcerogenicity of naproxen by complexation with ß-cyclodextrin. Int J Pharm 1991; 70: 35–41
- Paulus HE. Actions and toxicity of non-steroidal antiinflammatory drugs. Curr Opin Rheumatol 1995; 7: 159–166
- Reddy KVK, Rao DS, Vyas K, Reddy GO. LC method for the quantitative determination of oxaprozin and its impurities in the bulk drug. J Pharm Biomed Anal 2000; 22: 651–659
- Rothstein R. Safety profiles of leading nonsteroidal anti-inflammatory drugs. Am J Med 1998; 105: 39–43
- Sashmal S, Mukherjee S, Ray S, Thakur R, Ghosh LK, Gupta BK. Design and optimization of NSAID loaded nanoparticles. Pakistan J Pharm Sci 2007; 20: 157–162
- Song X, Zhao Y, Hou S, Xu F, Zhao R, He J, Cai Z, Li Y, Chen Q. Dual agents loaded PLGA nanoparticles: Systematic study of particle size and drug entrapment efficiency. Eur J Pharm Biopharm 2008; 69: 445–453
- Uekama K, Hirayama F, Tetsumi I. Cyclodextrin drug carrier systems. Chem Rev 1998; 98: 2045–2076
- Yang S, Zhu J, Lu Y, Liang B, Yang C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res 1999; 16: 751–762